Previous Article | Next Article ![]()
Applied and Environmental Microbiology, January 2009, p. 108-112, Vol. 75, No. 1
0099-2240/09/$08.00+0 doi:10.1128/AEM.01341-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
,
M. R. Gillings,1 and
M. L. Power1
Department of Biological Sciences, Macquarie University, Sydney, New South Wales 2109, Australia,1 Chemistry and Biomolecular Sciences, Macquarie University, Sydney, New South Wales 2109, Australia2
Received 16 June 2008/ Accepted 24 October 2008
|
|
|---|
|
|
|---|
Understanding the dynamics of human cryptosporidiosis requires species identification, so that transmission routes and contamination sources can be identified. C. parvum and C. hominis are morphologically indistinguishable, and consequently species can be identified only by using molecular techniques. DNA sequencing is the "gold standard" for identification, but it is too time-consuming and expensive for routine diagnostics. More rapid and cost-effective methods, such as restriction fragment length polymorphism (RFLP) analysis, are often used (5, 18, 25). The efficacy of RFLP analysis depends on the availability of diagnostic restriction sites and a suitably high titer of parasites. Diagnosis of low-level or mixed infections is more difficult, and the analysis may underestimate the contribution of each species to human disease and misidentify contamination sources. Hence, there is a need to develop sensitive and discriminatory diagnostic methods for identification of Cryptosporidium species.
Terminal RFLP (T-RFLP) analysis is a fluorescence-based PCR technology that has been used to measure demographic complexity and biodiversity in bacterial communities, including communities from marine environments, soil, groundwater, gut microbiota, and feces (3, 6, 14, 15, 17, 23, 24). T-RFLP analysis relies on polymorphisms in the positions of restriction sites relative to the position of a fluorescently tagged primer. The use of a single fluorescent primer limits the analysis to the terminal restriction fragment (T-RF) in a target DNA molecule (15). Samples can be analyzed using capillary electrophoresis and an automated DNA sequencer, which allows fine-scale size resolution and quantification of T-RF abundance (7). Variation in the sizes of T-RFs of different species enables differentiation.
Because T-RFLP is fast, sensitive, and amenable to high-throughput analysis (7, 10, 24), it warrants investigation as a diagnostic tool for Cryptosporidium. This paper describes the use of T-RFLP analysis to identify Cryptosporidium species present in human fecal samples. T-RFLP analysis proved to be a reliable and reproducible alternative method for detection and identification of Cryptosporidium species.
|
|
|---|
Oocyst purification and DNA extraction.
Fecal samples were exposed to 1,500 Ci from a 60Co source for 30 min. Cryptosporidium oocysts were purified using a sucrose flotation gradient as described by Truong and Ferrari (22). Purified oocysts, stained with the Cryptopsoridium-specific antibody CRY104 labeled with fluorescein isothiocyanate (Biotech Fronteirs, North Ryde, Australia), were examined using epifluorescence microscopy with appropriate filters for fluorescein isothiocyanate excitation (Axioscope; Zeiss, Germany) and were enumerated at a magnification of x400 (20). Genomic DNA was extracted from purified oocysts using PrepGEM (ZyGEM Corporation Ltd., Hamilton, New Zealand) as previously described (9).
Identification of Cryptosporidium species by PCR-RFLP analysis.
Amplification of the 18S rRNA gene was performed using a previously described nested PCR (27). The primary and secondary reaction mixtures contained 6 mM MgCl2, 200 µM deoxynucleoside triphosphates, 200 nM of each primer, 1 U of Red Hot Taq (ABgene, Surrey, United Kingdom), and 2 µl of DNA template. After an initial denaturation at 94°C for 3 min, a total of 35 cycles, each consisting of 94°C for 45 s, 56°C for 45 s, and 72°C for 1 min, were performed, followed by a final extension step of 72°C for 7 min. The secondary PCR mixture (total volume, 50 µl) contained 1 µl of the primary PCR product. The cycling conditions for the secondary reactions were identical to those used for the primary PCR. All PCRs were performed with a negative control containing only PCR water and a positive control containing C. parvum DNA. Reactions were performed with Eppendorf Mastercycler Personal instruments (Eppendorf, North Ryde, Australia), and products were resolved by electrophoresis on 1.5% (wt/vol) agarose gels using Tris-borate-EDTA. Secondary product fragments that were the correct size (832 to 835 bp depending on the species) were purified using a QIAquick PCR purification kit (Qiagen, Melbourne, Australia) by following manufacturer's instructions for the spin protocol.
RFLP analysis was performed using a previously described protocol with restriction enzyme VspI (10 U/µl; New England BioLabs) (27). DNA fragments were separated on 3.5% (wt/vol) agarose gels at 100 V for 50 min. The RFLP patterns of C. hominis and C. parvum were visualized under UV light after the preparations were stained with ethidium bromide (0.5 µg/ml) for 30 min.
Optimization of the T-RFLP protocol.
The T-RFLP protocol was optimized using six C. hominis isolates and six C. parvum isolates. Two loci of the 12 isolates, the 18S rRNA gene locus and the glycoprotein 60 locus, had previously been characterized to confirm the identities of the species. The 18S rRNA gene sequences of these isolates were used to determine the lengths of the expected T-RFs.
C. hominis and C. parvum were assessed independently to ensure that there was efficient amplification of both species. Optimization of the reaction for each species was accomplished by comparing four blunt end Taq polymerases, Pfu Turbo (Stratagene, La Jolla, CA) Accuzyme (Bioline, London, United Kingdom), Accutaq (Sigma-Aldrich, Australia), and Sahara (Bioline, United Kingdom), using two final concentrations of MgCl2 (4 and 6 mM). For fluorescence analysis the forward primer of the secondary reaction was fluorescently labeled at the 5' end with 6-carboxyfluorescein (Proligo, Lismore, Australia).
T-RFLP nested PCR.
The constituents used for primary and secondary reactions were identical to those described above except that Red Hot Taq was replaced by Accutaq (1 U) and dimethyl sulfoxide was added at a final concentration of 2%. The cycling conditions were initial denaturation at 94°C for 3 min, followed by 35 cycles, each consisting of 94°C for 45 s, 56°C for 45 s, and 68°C for 1 min, and then a final extension at 68°C for 7 min. For secondary PCRs that generated the expected products, the products were purified and subjected to restriction digestion with VspI. The amount of DNA in the restriction digest used for T-RFLP analysis was 10-fold less than the amount used for RFLP analysis due to the sensitivity of capillary electrophoresis.
Samples were analyzed at the Macquarie University DNA sequencing facility. Prior to capillary electrophoresis, 10 µl of HiDi/Standards master mixture comprising 9.9 µl of formamide and 0.1 µl of the internal DNA standard LIZ500 (Applied Biosystems) was added to 1 µl of template, and this was followed by denaturation at 95°C for 5 min. The fluorescence of the T-RFs was detected using an ABI Prism 3130x1 genetic analyzer (Applied Biosystems) in Genescan mode (8.5 kV; 40-s injection; 60°C for 100 min) with a G5 filter. T-RF sizes were determined using GeneScan software, version 4.0 (Applied Biosystems).
MDL of T-RFLP analysis.
To determine the minimum detection limit (MDL) of T-RFLP analysis, purified C. hominis and C. parvum oocysts were used to prepare suspensions with known numbers of oocysts of each species. Oocysts were immunolabeled with CRY104 as described above and sorted onto polycarbonate membranes using a FACSCalibur-sort flow cytometer (BD Biosciences, Sydney, Australia). C. hominis and C. parvum oocyst suspensions were prepared in triplicate and contained 1, 10, 100, and 1,000 oocysts. To confirm numbers of oocysts, membranes containing 1 or 10 oocysts were examined using epifluorescence microscopy as described above. DNA extraction and T-RFLP analysis were then conducted as previously described.
Mixed-infection detection.
Mixed-species suspensions were used to determine the sensitivity of T-RFLP analysis for detection of mixed infections. Purified oocysts of C. hominis and C. parvum were immunolabeled and sorted using a fluorescence-activated cell sorter as described above. Triplicate samples containing 500 oocysts were prepared using the following ratios of C. hominis to C. parvum: 1:99, 5:95, 10:90, 25:75, 50:50, 75:25, 90:10, 95:5, and 99:1. DNA was extracted using prepGEM, and amplification for T-RFLP analysis was performed as described above. For comparison, RFLP analysis was performed with mixed-species suspensions as described by Xiao et al. (27).
|
|
|---|
![]() View larger version (41K): [in a new window] |
FIG. 1. Species identification of Cryptosporidium isolates by RFLP (A) and T-RFLP (B) analyses of the 18S rRNA gene with VspI. C. hominis isolates (lanes 3 to 5, 9, and 10) produced three fragments but were identified by the presence of the 69- and 530-bp fragments, whereas C. parvum isolates (lanes 6 to 8) were identified by a 627-bp fragment. T-RFLP analysis was used to identify C. hominis by a 64-bp peak and C. parvum by a 624-bp peak.
|
The T-RFLP results differentiated C. hominis and C. parvum based on the fluorescently labeled 5' T-RFs. C. hominis isolates generated a 64-bp T-RF, and C. parvum isolates generated a 624-bp T-RF (Fig. 1B). A second T-RF with an estimated size of 621 bp was detected in the profiles of all C. parvum isolates. The intensity of the second peak was consistently less than the intensity of the 624-bp T-RF peak.
Comparison of T-RFLP analysis to RFLP analysis produced consistent results, and the organisms in each sample were identified as the same species by both methods (see File S1 in the supplemental material). One sample, isolate 24, which did not produce a visible RFLP product when it was resolved using gel electrophoresis, was identified as C. parvum by T-RFLP analysis. Eight isolates were not identified by T-RFLP analysis after 6 months of storage.
MDL for T-RFLP analysis.
The MDL for T-RFLP analysis was higher than the MDL for RFLP analysis. For C. parvum, RFLP analysis was able to resolve DNA from a single oocyst, but for C. hominis RFLP products were observed in only one of the three samples containing DNA from a single oocyst (Table 1; see also File S2 in the supplemental material). Despite using 10-fold less DNA template than RFLP analysis, T-RFLP analysis detected the expected T-RF for all three C. hominis samples which contained DNA from a single oocyst (see File S3 in the supplemental material).
|
View this table: [in a new window] |
TABLE 1. Detection of C. hominis and C. parvum in samples with known numbers of oocysts
|
![]() View larger version (34K): [in a new window] |
FIG. 2. Detection of C. hominis and C. parvum at different ratios in mixed populations. (a) Analysis of mixed-species suspensions identified C. parvum DNA at all C. parvum/C. hominis ratios. Lane 1, molecular weight marker; lane 2, negative control; lane 3, C. hominis control; lane 4, C. parvum control; lanes 5 to 7, 1:99 ratio; lanes 8 to 10, 5:95 ratio; lanes 11 to 13, 10:90 ratio; lanes 14 to 16, 25:75 ratio; lanes 17 to 19, 50:50 ratio. (b) C. hominis DNA could not be detected by RFLP analysis at the majority of the ratios. The only exception was sporadic amplification in the samples containing C. hominis and C. parvum at a ratio of 5:95 (lanes 8 to 10).
|
|
View this table: [in a new window] |
TABLE 2. Detection of C. hominis and C. parvum when different ratios in mixed populations were used
|
|
|
|---|
Although five Cryptosporidium species are known to cause disease in humans (16, 18, 28), this study was performed to develop T-RFLP analysis of the 18S rRNA genes to differentiate C. hominis and C. parvum. T-RFLP analysis unambiguously differentiated between C. hominis and C. parvum isolates and identified the C. hominis-specific peak at 64 bp and the C. parvum-specific peak at 624 bp. Due to the heterogeneity in the 18S rRNA genes of C. parvum isolates, the electropherograms for these isolates had a second minor peak at 621 bp, which was attributed to the second, type B copy of the 18S rRNA gene (13). The mobilities calculated by the GeneScan software were approximately the same as the mobilities expected for the two species, 69 bp for C. hominis and 627 bp for C. parvum. To maintain accurate species identification and to correct for run variation, a panel of reference controls should be included in each analysis run. The reliability and reproducibility of T-RFLP analysis for identification of Cryptosporidium species is high, and the T-RFs for all samples were consistent with previous sample identifications. The DNA extraction method used in this study is new (9), and no stability data have been reported yet. It is possible that the failure to reamplify the DNA of eight isolates was due to degradation over the 6 months of storage. The DNA stability after extraction with PrepGEM needs to be evaluated if this method is to be used for preparation of Cryptosporidium libraries.
Mixed infections are not commonly detected in cases of human cryptosporidiosis. It has been proposed that when C. hominis and C. parvum simultaneously infect the same host, C. parvum displaces C. hominis and becomes the predominant parasite (1). Mixed-species analyses in this study indicated that preferential amplification of C. parvum DNA occurs regardless of its relative contribution to the DNA pool. Both RFLP and T-RFLP analyses failed to consistently detect C. hominis DNA when its contribution to the DNA pool was equal to or less than that of C. parvum. Similar results were obtained in a previous study which used different nested primer sets (21), and this suggests that mixed infections may occur more frequently than has been recorded. The limitations of selective amplification by PCR mean that previous studies of human cryptosporidiosis have overlooked the contribution of C. hominis and other pathogenic species to human disease. This would have limited the identification of all possible disease sources.
Accurate identification of all species causing human cryptosporidiosis should increase our understanding of both the disease dynamics and the sources of infection. Here, C. hominis and C. parvum were the only species used, but altering the restriction enzyme would allow T-RFLP analysis to be used for identification of other Cryptosporidium species of concern to human health, such as Cryptosporidium meleagridis, Cryptosporidium canis, and Cryptosporidium muris, which can be differentiated using SspI (26).
The use of T-RFLP analysis in epidemiological studies should provide rapid, reproducible, and accurate identification of Cryptosporidium species in infections. The MDL and the sensitivity of T-RFLP analysis to a single oocyst should improve prevalence estimates. The methodology developed in this study will be used in an ongoing investigation of human cryptosporidiosis in New South Wales, Australia.
We thank Jeremy McAnulty and Jennie Musto of the NSW Health Communicable Disease Branch for their assistance with sample collection. We especially acknowledge Douglas Hanley Moir, SDS Pathology and Symbion in North Ryde and the Westmead, Australia, John Hunter, St. Vincents, Blacktown, Gosford, Australia, David Campbell, and the Wollongong and Seals hospitals for providing human fecal samples.
Published ahead of print on 31 October 2008. ![]()
Supplemental material for this article may be found at http://aem.asm.org/. ![]()
Present address: School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney NSW 2052, Australia. ![]()
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»